Antidepressant efficacy of agomelatine versus SSRI/SNRI: Results from a pooled analysis of head-to-head studies without a placebo control

International Clinical Psychopharmacology

Volumn 28, Issue 1, 2013, Pages 12-19

  Kasper, Siegfried ^a   Corruble, Emmanuelle ^b   Hale, Anthony ^e   Lemoine, Patrick ^c   Montgomery, Stuart A ^f   Quera Salva, Maria Antonia ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BICÊTRE HOSPITAL   (France)

^c Clinique Lyon Lumière   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

agomelatine; antidepressant; escitalopram; fluoxetine; paroxetine; sertraline; tolerability; venlafaxine

Indexed keywords

AGOMELATINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; HAMILTON SCALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL;

ACETAMIDES; ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871618800     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328359768e     Document Type: Article

References (33)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
3. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
4. Corruble E (2011). Agomelatine versus escitalopram in major depressive disorders: a randomized double-blind long term study focusing on sleep satisfaction and emotional blunting. European Congress of Psychiatry, Vienna, 12-15 March 2011. Eur Psychiatry 26 (S1):619.
5. European Medicines Agency (2009). European Public Assessment Report. Valdoxan. Avaliable at: http://www. ema. europa. eu [Accessed 31 August 2012].
6. Goodwin GM, Emsley R, Rembry S, Rouillon F (2009). Agomelatine prevents relapse in patients with major depressive disorder, without evidence of discontinuation syndrome. J Clin Psychiatry 70:1128-1137.
7. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25:305-314.
8. Hickie IB, Rogers NL (2011). Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621-631.
9. Huf W, Kalcher K, Pail G, Friedrich ME, Filzmoser P, Kasper S (2011). Metaanalysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 12:188-200.
10. Kasper S, Hamon M (2009). Agomelatine, a new antidepressant with an innovative mechanism of action-an overview on its preclinical and clinical development program. World J Biol Psychiatry 10:117-126.
11. Kasper S, Hajak G, Wulff K, Hoogendijk WI, Montejo AL, Smeraldi E, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with Major Depressive Disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109-120.
12. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100. (Pubitemid 43145814)
13. Kennedy SH, Rizvi SJ (2010). Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 24:479-499.
14. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122-131.
15. Kennedy SH, Rizvi S, Fulton K, Rasmussen J (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28:329-333.
16. Khan A, Detke M, Khan SR, Mallinckrodt C (2003). Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 191:211-218. (Pubitemid 36522920)
17. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011). Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72:464-472.
18. Laux G (2012). The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry (in press). doi: 10. 1055/s-0032-1309003.
19. Lemoine P, Guilleminault C, Alvarez E (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723-1732. (Pubitemid 350247502)
20. Licht RW, Qvitzau S (2002). Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 161:143-151. (Pubitemid 34492659)
21. Loo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
22. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747-1757. (Pubitemid 43767064)
23. Montgomery SA, Kasper S (2007). Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283-291. (Pubitemid 47237547)
24. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280. (Pubitemid 39141943)
25. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329. (Pubitemid 47530836)
26. Murray CJ, Lopez AD (1997). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442. (Pubitemid 27212192)
27. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 63:424-434.
28. Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673. (Pubitemid 47517525)
29. Quera Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gal S, Laredo J, et al. (2011). Comparative effects of agomelatine and escitalopram in sleep in MDD patients. Int Clin Psychopharmacol 26:252-262.
30. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, et al. (2011). Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry 12:574-587.
31. Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickels K (2001). The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 16:137-143. (Pubitemid 32402358)
32. Wernicke JF, Bosomworth JC, Ashbrook E (1989). Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 4 (Suppl 1):63-67.
33. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679.